Custom Index Systems LLC Raises Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Custom Index Systems LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,290 shares of the company’s stock after buying an additional 37 shares during the period. Custom Index Systems LLC’s holdings in Medpace were worth $429,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of MEDP. R Squared Ltd bought a new stake in Medpace during the 4th quarter valued at $30,000. Stone House Investment Management LLC purchased a new position in shares of Medpace in the third quarter valued at about $33,000. Ashton Thomas Securities LLC purchased a new stake in shares of Medpace during the third quarter worth about $37,000. Capital Performance Advisors LLP bought a new stake in shares of Medpace in the third quarter worth about $46,000. Finally, True Wealth Design LLC increased its holdings in Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after purchasing an additional 168 shares during the period. 77.98% of the stock is owned by institutional investors.

Medpace Trading Down 0.3 %

Shares of MEDP opened at $349.15 on Friday. The firm has a fifty day simple moving average of $342.28 and a two-hundred day simple moving average of $353.35. The firm has a market cap of $10.85 billion, a PE ratio of 30.57, a P/E/G ratio of 1.76 and a beta of 1.36. Medpace Holdings, Inc. has a 1-year low of $286.76 and a 1-year high of $459.77.

Analyst Upgrades and Downgrades

MEDP has been the subject of several research reports. William Blair restated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Robert W. Baird boosted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. TD Cowen lowered their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Redburn Atlantic began coverage on Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 target price on the stock. Finally, Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.